Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

CASR (Calcium-Sensing Receptor)

Written2013-09Bryan Ward, Aaron Magno, Thomas Ratajczak
Department of Endocrinology, Diabetes, Sir Charles Gairdner Hospital, UWA Centre for Medical Research, The University of Western Australia, Nedlands, Western Australia, 6009, Australia

(Note : for Links provided by Atlas : click)


HGNC Alias symbFHH
HGNC Alias namesevere neonatal hyperparathyroidism
HGNC Previous nameHHC
HGNC Previous namehypocalciuric hypercalcemia 1
 calcium-sensing receptor
LocusID (NCBI) 846
Atlas_Id 43977
Location 3q21.1  [Link to chromosome band 3q21]
Location_base_pair Starts at 122184327 and ends at 122291628 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping CASR.png]
Local_order Chromosome: 3; NC_000003.11.
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
FAM162A (3q21.1)::CASR (3q13.33)FAM162A (3q21.1)::CASR (3q21.1)LPP (3q28)::CASR (3q13.33)
LPP (3q28)::CASR (3q21.1)SUCLA2 (13q14.2)::CASR (3q13.33)SUCLA2 (13q14.2)::CASR (3q21.1)
Note Genbank Accession number: U20760; EMBL-Bank Accession number: X81086.


  Figure 1. Schematic representation of the calcium-sensing receptor (CaSR) gene structure (A), promoter location and features (B) and protein structural arrangement (C). The CaSR mRNA is transcribed from part of exon 2, all of exons 3 to 6 and part of exon 7. Exons that comprise the CaSR protein are shaded yellow; untranslated exons are left unshaded. Note that intronic regions are not drawn to scale. The location of polyadenylation sites (AAA) within the untranslated region of exon 7 are arrowed. In B, the spatial relationship between promoters P1 and P2 (hatched) and untranslated exons 1A and 1B (unshaded) is highlighted along with the position of various transcription factor binding sites and regulatory elements: C, CCAAT box; T, TATA box; A, Ap-1 sites; *, serum response elements; VRE, vitamin D response elements; G, glial cells missing-2 response element; ↑, Sp1 sites; NFκB, NFκB response elements; S, STAT sites (S1 regulates IL-6 response). The CaSR protein (C) is composed of the extracellular domain (ECD) consisting of a signal peptide (SP), Venus Fly Trap (VFT) domain and cysteine-rich domain (Cys) connected by a small linker region (L) to the seven transmembrane domain (7TM) and intracellular tail, both encoded by exon 7.
Description The human CaSR gene maps to 3q13.3-21, is approximately 103 kb in length and contains 8 exons (exons 1A and 1B and exons 2-7) (Garrett et al., 1995; Janicic et al., 1995; Hendy et al., 2009). The full length CaSR protein is translated from part of exon 2, all of exons 3-6 and part of exon 7 (Figure 1). Exons 1A and 1B are not translated. An alternatively spliced, functional variant of the receptor lacking exon 5 has been reported (Rodriguez et al., 2005a). The CaSR gene has two promoters, an upstream promoter (P1) containing a TATA box and CCAAT box and an additional promoter (P2) with Sp1 sites that cluster near the transcriptional start site (Figure 1; Chikatsu et al., 2000; Canaff et al., 2008; Hendy et al., 2009). The two promoters yield alternative transcripts containing either exon 1A or exon 1B spliced to exon 2 (Chikatsu et al., 2008; Hendy et al., 2009). Both promoters contain vitamin D response elements as well as response motifs for NF-κB and glial cells missing-2 (Canaff and Hendy, 2002; Canaff and Hendy, 2005; Canaff et al., 2009). The upstream promoter region contains Stat1/stat3 elements which allow for response to interleukin-6 (Canaff et al., 2008). Use of differential polyadenylation signals in exon 7 appear to lead to at least two different-sized 3' untranslated regions (Figure 1; Garrett et al., 1995).


Note The full length human CaSR mRNA encodes a protein of 1078 amino acids consisting of a 612 amino acid signal peptide/extracellular domain (ECD), a 250 amino acid seven transmembrane domain (7TM) and an unusually long 216 amino acid intracellular tail (Garrett et al., 1995; Hu and Spiegel, 2003) (Figure 1). The NH2-terminal signal peptide is 19 amino acids in length and directs the nascent protein to the endoplasmic reticulum (ER) where it is subsequently removed (Hu and Spiegel, 2003; Pidasheva et al., 2005; Hendy et al., 2009). The ECD is composed of a bilobed Venus flytrap (VFT) domain followed by a cysteine-rich domain connected via a peptide linker region to the 7TM which in addition to the membrane α-helices also contains three intra- and three extra-cellular loops; the final TM α-helix is connected to the intracellular tail, the membrane proximal domain of which is important for receptor cell expression and intracellular signalling (Ray et al., 1997; Hu and Spiegel, 2003). The CaSR protein is processed as a dimer in the ER via covalent intermolecular disulphide bonds and hydrophobic interactions and functions as a dimer when mature (Bai et al., 1998; Bai et al., 1999; Zhang et al., 2001; Pidasheva et al., 2006). Essentially, agonist binding to a cleft between the VFT lobes of each monomer leads to their closure and rotation about the VFT dimer interface thus transmitting a conformational change to the cysteine-rich domain which in turn allows movement of the 7TM α-helices with respect to one another resulting in connection of G proteins to the intracellular loops and initiation of signalling pathways (Hu and Spiegel, 2003). The CaSR contains 11 potential N- linked glycosylated sites in the ECD and is glycosylated in the ER with high mannose carbohydrates (immature receptor) after which it is transported to the Golgi where it is further modulated with complex carbohydrates (mature receptor) (Ray et al., 1998). Western blot analysis of protein extracted from cells containing mature and immature CaSR reveal bands at 150 kDa and 130 kDa, respectively. The CaSR contains five potential sites for protein kinase C phosphorylation, two in intracellular loops 1 and 3 and three in the intracellular tail and two potential sites for protein kinase A phosphorylation in the intracellular tail (Garrett et al., 1995; Bosel et al., 2003).
Description The CaSR was first cloned from bovine parathyroid cells by Brown and coworkers in 1993 and the human receptor was cloned from an adenomatous parathyroid gland in 1995 (Brown et al., 1993; Garrett et al., 1995). The CaSR is a G protein-coupled receptor belonging to Group II of Family C, G protein-coupled receptors and conforms to a typical G protein-coupled receptor structure with a large extracellular domain, a seven transmembrane spanning domain and a rather large intracellular tail (Brown and MacLeod, 2001; Hu and Spiegel, 2003). The CaSR is promiscuous, activating a variety of signalling pathways via a host of ligands (in addition to Ca2+) in a cell/tissue type-specific manner (Brown and MacLeod, 2001; Magno et al., 2011b). The receptor's primary function is in the maintenance of calcium homeostasis in the body, but other functions have more recently come to light (see below).
Expression The CaSR has a widespread tissue distribution in the body including those tissues which are important in the maintenance of calcium homeostasis, namely the chief cells of the parathyroid gland where it is responsible for regulating parathyroid hormone (PTH) secretion, the C cells of the thyroid whereby it controls calcitonin secretion, the kidney where it controls calcium reabsorption, the placenta whereby it controls calcium transport from mother to foetus and in cartilage and bone cells, (chondrocytes, osteoblasts and osteoclasts) in which it has important effects on the laying down and maintenance of the skeleton (Magno et al., 2011b; Riccardi and Kemp, 2012). The CaSR is also expressed in intestinal epithelial cells where it serves to regulate intestinal uptake of calcium by directly modulating responsiveness to 1,25-dihydroxyvitamin D (Egbuna et al., 2009). Apart from tissues which regulate calcium homeostasis, the CaSR is also expressed in many tissues outside this realm including the breast, ovary, uterus, testis, prostate and germ cells, the tongue, oesophagus, stomach and pancreas as well as the heart, various parts of the brain (including the subfornical organ and olfactory bulbs, hippocampus, hypothalamus and cerebellum), pituitary, lens epithelium and skin (Brown and MacLeod, 2001; Magno et al., 2011b; Riccardi and Kemp, 2012). The function of the CaSR in many of these tissues is still largely unknown.
Localisation As expected for a G protein-coupled receptor, the CaSR localizes to the plasma membrane of the cells in which it is expressed. However, there is accumulating evidence for a large intracellular pool of receptor that localizes to the ER/Golgi awaiting agonist driven trafficking to the plasma membrane, a mechanism thought to regulate membrane CaSR abundance in the chronic presence of agonist (Grant et al., 2011). While the CaSR does undergo endocytosis and is targeted to the lysosome, it does not undergo substantial desensitization and recycling as occurs with many other G protein-coupled receptors (Grant et al., 2011). In the chief cells of the parathyroid gland, CaSR is located in caveolae, flask-like invaginations of the plasma membrane that contain various signalling molecules and scaffolding proteins such as filamin-A and caveolin-1 to which the CaSR is anchored (Kifor et al., 1998). In various parts of the kidney tubule (proximal tubule, cortical thick ascending limb, distal convoluted tubule, medullary collecting duct) the membrane bound CaSR may be located apically or basolaterally or both depending on its specific function(s) in these compartments (Riccardi and Kemp, 2012). For example, the apically located CaSR in the medullary collecting duct inhibits insertion of AQP2 water channels and promotes activation of the B1 subunit of the vacuolar H+-ATPase in the apical membrane, thus delivering a less concentrated and more acidified urine (Sands et al., 1998; Procino et al., 2004; Riccardi and Kemp, 2012). Likewise in the gastrointestinal tract, the CaSR is expressed both on the apical and basolateral membranes of the gastrin secreting G cells of the stomach indicating that it can sense and respond to nutrient levels both in the lumen and in the blood, whereas CaSR in colonic epithelial cells, whether it is expressed apically or basolaterally, can mediate cAMP-mediated fluid secretion (Conigrave and Brown, 2006).
Function The primary function of the CaSR is in the maintenance of calcium homeostasis through regulation of PTH secretion and reabsorption of calcium from the kidney tubules. PTH has effects on bone resorption, intestinal uptake of calcium (via production of 1,25-dihydroxyvitamin D) and calcium reabsorption from the kidney, all combining to restore calcium in the extracellular fluid to a concentration within the narrow range 1.1 - 1.3 mM Ca2+ (Tfelt-Hansen and Brown, 2005). However, the CaSR is now known to be a multifunctional receptor with important influences on major cellular processes that include not only entero-endocrine secretion but control of gene expression and cell differentiation, cellular proliferation, apoptosis, chemotaxis, cytoskeletal organization and the regulation of ion transport and the activity of ion channels (Tfelt-Hansen and Brown, 2005; Riccardi and Kemp, 2012). It achieves this enormous diversity of function by activating an array of cell signalling pathways in a tissue and ligand-dependent manner, with partner binding proteins also playing an important role (Brennan and Conigrave, 2009; Magno et al., 2011b). The CaSR can be activated not only by Ca2+ ions but by other di-, tri- and polyvalent cations including polyamines such as spermine, aminoglycoside antibiotics such as neomycin and polypeptides including amyloid β-peptide. Receptor activity is also modulated by pH and salinity and can be potentiated (in the presence of direct agonist) by allosteric activators such as L-amino acids and type II calcimimetics (Nemeth et al., 1998; Conigrave et al., 2000; Brown and MacLeod, 2001; Magno et al., 2011b). The receptor, upon activation, can couple to Gq/11, Gi/0, G12/13 and Gs G protein families to regulate a variety of signalling molecules including phosphatidylinositol-specific phospholipase C (PLC) (and hence PKC and release of intracellular Ca2+ from intracellular stores), as well as phospholipase A2, phosphatidylinositol 3-kinase (which in turn affects Akt signalling), phospholipase D and Rho and MAP kinases (including ERK1/ERK2) (Brennan and Conigrave, 2009; Magno et al., 2011b). When coupled to Gs and Gi the receptor can stimulate or inhibit cAMP production, respectively (Mamillapalli et al., 2008).
The precise pathway(s) involved in CaSR-mediated inhibition of PTH have yet to be completely elucidated, however the associated reduction in PTH mRNA levels involves an increase in intracellular Ca2+, suggesting a role for PLC activation (Ritter et al., 2008). The CaSR has several important homeostatic functions in the kidney depending on its location. In the proximal tubule, CaSR stimulation reverses the inhibitory effects of PTH on phosphate reabsorption via the phosphate transporters NaPi-IIa/NaPi-IIc and also blocks 2,5-hydoxyvitamin D3-1 α-hydroxylase. In the thick ascending limb of Henle's loop, stimulation of basolaterally localized CaSR reduces potassium cycling (by decreasing the activity of the 70-pS channel) as well as NaCl transport and paracellular reabsorption of Mg2+ and Ca2+. In the distal convoluted tubule, the CaSR is located both apically and basolaterally, in the former it is linked to the receptor potential vanilloid member 5 (TPRV5) and stimulation of the CaSR therefore increases uptake of Ca2+ ions. Basolaterally, CaSR activation inhibits the activity of plasma membrane Ca2+-ATPase 1b and decreases expression of the K+ channel, Kir4.1 resulting in inhibition of basolateral K+ recycling. Activation of apically located CaSR in the medullary collecting duct reduces osmotic water permeability (creating less concentrated urine) by inhibiting vasopressin-induced insertion of AQP2 water channels and increases the activity of H+ -ATPase (making urine more acidic). These effects reduce the likelihood of kidney stone formation (see recent reviews that discuss the functional homeostatic role for the receptor in the kidney by Magno et al., 2011b and Riccardi and Kemp, 2012). The CaSR is also expressed in regions of the kidney that do not relate to Ca2+ or other mineral ion homeostasis. Activation of the CaSR expressed in the juxtaglomerular cells of the afferent arteriole of the kidney inhibits release of renin, thus exerting influence over the renin-angiotensin system that controls blood pressure (Atchison et al., 2010) while stimulation of the CaSR in the podocytes of the glomerular filter has been shown to effect the cytoskeletal integrity and viability of these cells suggesting an important role for the receptor in proper renal filtration (Oh et al., 2011).
The CaSR is expressed along the whole length of the gastrointestinal tract where it plays important roles in nutrient sensing, the regulation of fluid secretion, hormone release and cell differentiation/apoptosis (Conigrave and Brown, 2006; Geibel and Hebert, 2009). Recent data show that taste buds contain the CaSR and that agonists of the CaSR enhance taste perception while antagonists of the CaSR suppress it (Ohsu et al., 2010). The receptor is also expressed in the basal cells of the oesophagus where stimulation results in an increase in IL-8 secretion, the physiological importance of which is yet to be determined (Justinich et al., 2008). In the stomach, the CaSR plays a clear role in the regulation of gastrin and gastric acid release from G cells and parietal cells, respectively (Conigrave and Brown, 2006; Geibel and Hebert, 2009). In the duodenum, amino acid stimulation of the CaSR in I cells of the small intestine leads to release of cholecystokinin a hormone important for gall bladder contraction, pancreatic enzyme secretion and gastric emptying (Wang et al., 2011). CaSR expression in the acinar cells of the pancreas and in pancreatic duct cells suggests a role for the receptor in fluid secretion and/or the secretion of enzymes from the pancreas (Racz et al., 2002; Riccardi and Kemp, 2012). The proper regulation of fluid secretion from the pancreatic ducts by the CaSR is thought to be important in the prevention of pancreatic stones and pancreatitis (Riccardi and Kemp, 2012). In addition, activation of the CaSR expressed in the β-cells of the pancreatic islets of Langerhans can modulate insulin secretion and this has implications for the onset and progression of diabetes (Gray et al., 2006; Squires et al., 2000). CaSR expression in colonic epithelial cells is required for the transition of cells along the crypt from a proliferative to a differentiated state, thus the presence of receptor in these cells is thought to be important in preventing colon cancer (Whitfield, 2009). Agonist activation of the CaSR in the colon can suppress cAMP-mediated fluid loss and is important in the control of NaCl and water absorption (Geibel and Hebert, 2009). It has been proposed that calcimimetics could be used to prevent diarrhoea/fluid loss associated with bacterial toxins in diseases such as cholera (Geibel et al., 2006).
In the lactating breast, expression of the CaSR in mammary epithelial cells can regulate parathyroid hormone-related protein (PTHrP) production and adjust uptake of calcium into milk according to calcium availability (VanHouten et al., 2004). In the normal breast the CaSR has tumour suppressor properties acting in concert with the BRCA1 tumour suppressor to decrease levels of the antiapoptotic protein, survivin, and increase sensitivity to paclitaxel, a drug commonly used in breast cancer treatment (Promkan et al., 2011). However, if expressed in malignant breast cells, the receptor may actually aid bone metastasis (see below under hypercalcaemia of malignancy). With relevance to its apparent role in metastasis, the CaSR has been shown to couple to integrins thereby promoting tumour cell adhesion and migration (Tharmalingham et al., 2011). The CaSR can also bind the focal adhesion protein, testin, that is known to have important effects on cell spreading and motility (Magno et al., 2011a).
In the brain, The CaSR is highly expressed in the subfornical organ and potentiates neuronal, hyperpolarization-activated inward currents, consistent with the bursting of action potentials in these neurons that has also been shown to be CaSR-potentiated (Washburn et al., 2000; Yano et al., 2004). The expression of the CaSR in the subfornical organ, which is a thirst control centre, suggests that the receptor plays a crucial role in fluid and electrolyte homeostasis. The CaSR also controls neuronal excitability in a number of other parts of the brain by regulating ion channels and this may contribute to its apparent role in epilepsy (Kapoor et al., 2008; Riccardi and Kemp, 2012). For example, in the hippocampus, CaSR-mediated activation of a voltage-independent Na+ leak conductance channel leads to neuronal excitation (Lu et al., 2010). In the hippocampus, increasing expression of the CaSR during the first weeks of life correlate with long-term potentiation indicating that the CaSR may play a role in cognitive functions such as memory and learning (Brown and MacLeod, 2001; Yano et al., 2004). The CaSR has important regulatory effects on the developing nervous system, for example, activation of the CaSR appears to be critical for the expansion and differentiation of oligodendrocyte progenitor cells and the generation of myelin in preoligodendrocytes (Chattopadhyay et al., 2008). Stimulation of CaSR is required for the production of a cofactor, tetrahydrobiopterin, essential for the activation of nitrous oxide that is produced (in its inactive form) in response to amyloid β peptide-mediated activation of the receptor (Dal Pra et al., 2005). Hence, CaSR may play an important role in late onset Alzheimer's disease that is characterized by nitrous oxide-mediated neuronal damage. In the pituitary gland, activation of the CaSR stimulates cAMP production via coupling to Gαs with subsequent secretion of PTHrP and ACTH (Mamillapalli and Wysolmerski, 2010).
The CaSR is expressed and plays a functionally important role in various bone cells including osteoblasts/osteocytes and osteoclasts and their precursors, bone marrow derived stromal cells, monocyte-macrophage cells, chondrocytes and haematopoietic stem cells (Yamaguchi, 2008). Targeted depletion of the CaSR induced in mouse embryonic chondrocytes and osteoblasts has revealed that the CaSR is absolutely required for growth plate and skeletal development (Chang et al., 2008). Activation of the CaSR in osteoblasts is required for osteoblast differentiation, proliferation and mineralization (Yamaguchi, 2008; Dvorak-Ewell et al., 2011). In addition, high Ca2+-induced apoptosis of osteoclasts is mediated through nuclear translocation of NF-κB which in turn is dependent on CaSR stimulation and activation of PLC (Mentaverri et al., 2006). The CaSR also appears to be important in osteoclastogenesis as shown in studies with bone marrow cells from CaSR knockout mice (Dvorak-Ewell et al., 2011). The CaSR is required for haemopoietic stem cells to lodge in the endosteal niche of the bone marrow - this has implications for the proper functioning of erythropoiesis (Adams et al., 2006). The CaSR appears to contribute, albeit indirectly, to the formation of teeth and the development of dental alveolar bone (Sun et al., 2010).
The CaSR also has established roles in other organs and tissues including the heart and circulatory system. In the heart, the receptor can augment angiotensin II-mediated cardiac hypertrophy in cardiomyocytes, while CaSR-mediated production of nitrous oxide can lead to vasodilation in human aortic epithelial cells with subsequent effects on blood pressure (Ziegelstein et al., 2006; Wang et al., 2008). The CaSR has also been shown to mediate the cardio-protective effects of ischaemic preconditioning (Sun and Murphy, 2010). Expression of the CaSR in vascular smooth muscle cells of human arteries appears to be important in preventing arterial calcification (Alam et al., 2009). The CaSR appears to play an important role in the differentiation of keratinocytes and their survival (Tu et al., 2008). Lens epithelial cells express CaSR mRNA and protein and stimulation of the receptor regulates a calcium-activated potassium channel - it is likely that the receptor contributes to lens integrity (Chattopadhyay et al., 1997; Brown and MacLeod, 2001).
The receptor also has functional effects on reproduction and development (Riccardi and Kemp, 2012). The CaSR is expressed in ovarian surface cells and ova (where it is important for development and maturation), sperm (where it is important for maturation, motility and fertilization) and uterus (where it plays roles in implantation and embryonic development). Hence its proper expression has important implications for fertility. In addition the receptor plays a critical role in the placenta and in embryonic and foetal development of organs such as the lung, brain and nervous system (Riccardi and Kemp, 2012).
Homology The human and bovine CaSR share significant homology (greater than 90% at the amino acid level) with CaSRs from other mammals such as rodents, rabbits and cats (Garrett et al., 1995; Brown and MacLeod, 2001; Gal et al., 2010). Even CaSRs from chickens and the mudpuppy (an amphibian) share approximately 80% amino acid identity underscoring the functional importance of this receptor throughout the animal kingdom (Brown and MacLeod, 2001). The CaSR belongs to Family C of the G protein-coupled receptors, members of which share at least 20% amino acid homology in their seven transmembrane domains (Brauner-Osborne et al., 2007). Group I of Family C comprise the metabotropic glutamate receptors (mGluR 1-8) whereas the CaSR belongs to Group II which also contains the vomeronasal and taste and odorant receptors and various orphan receptors including GPRC6A (the most closely related to the CaSR). Group III comprises the gammabutyric acid (GABAB) receptors). Interestingly, the CaSR can heterodimerize with mGluR and GABAB receptors resulting in receptor units with unique pharmacological profiles (Gama et al., 2001; Cheng et al., 2007). The ECD including the VFT of the Family C GPCRs shares homology with bacterial periplasmic nutrient-binding proteins (PBPs) and Family C GPCRs are thought to have evolved from fusion of an ancient PBP-like structure (forming the ECD) with an independently derived seven transmembrane domain entity (Brown and Macleod, 2001).


Note Heterozygous, germinal mutations in the CaSR may be activating or inactivating leading to the familial conditions of altered calcium sensing, autosomal dominant hypocalcaemia (ADH) and familial hypocalciuric hypercalcaemia (FHH), respectively (Pollak et al., 1993; Pollak et al., 1994). These disorders are usually benign and may often be asymptomatic, although in rare cases severe activating mutations of the CaSR may give rise to Bartter's syndrome subtype IV (Vargas-Poussou et al., 2002). On the other hand, the homozygous presence of inactivating mutations or compound heterozygous mutations affecting both alleles of the CaSR gene give rise to the rare, but much more serious condition, neonatal severe hyperparathyroidism (NSHPT), that normally requires surgical intervention (usually sub-total parathyroidectomy) in the neonate (Pollak et al., 1993; Ward et al., 2004; Ward et al., 2012). Reported mutations leading to ADH and FHH/NSHPT number around 65 and 140, respectively and may occur almost anywhere in the CaSR gene coding region, although there is a particular preponderance in exons 3 and 4 which encode part of the extracellular ligand-binding domain that includes the VFT, and the 5' end of exon 7 which encodes the seven transmembrane, signalling domain, including the extra- and intracellular loops (Hendy et al., 2009 and see database: CASRdb).

Implicated in

Entity Primary and secondary hyperparathyroidism
Note Primary hyperparathyroidism (PHPT) is most commonly caused by a single adenomatous parathyroid gland, although it can occasionally arise from double adenomas or hyperplasia of all four glands. The condition arises from suppression of the Ca2+-induced negative feedback mechanism that controls PTH secretion - essentially there is a higher set point for Ca2+-induced inhibition of PTH secretion (Cetani et al., 2000). Unlike the inherited disorders of calcium homeostasis described in the above section, CaSR mutations have not been associated with the adenomas that give rise to PHPT, rather mutations in other genes such as the MEN1 tumour suppressor and cyclin D1 oncogene predominate (Hosokawa et al., 1995; Sharretts and Simonds, 2010). However, adenomas associated with PHPT have been shown to express low levels of CaSR compared to normal parathyroid tissue (Kifor et al., 1996; Ward et al., 2012). While the reason for this reduced expression is unclear, it does lead to an exacerbation of the condition since the CaSR contributes to the altered set point for PTH release. In addition, there is further evidence for the involvement of the CaSR in PHPT: impaired CaSR-mediated amino acid sensing (as well as calcium sensing) can cause loss of negative feedback of PTH release (Mun et al., 2009) and specific allosteric activators of the CaSR (calcimimetics) have been used successfully in the treatment of PHPT (Peacock et al., 2009). Finally, various polymorphisms in the CaSR gene or its regulatory region have been linked to PHPT and/or the severity of its clinical manifestations (reviewed in Ward et al., 2012). Secondary hyperparathyroidism (SHPT) which most commonly arises from chronic kidney disease (CKD) is controlled by the CaSR as well as other factors that regulate calcium and phosphate homeostasis (Rodriguez et al., 2005b, Ward et al., 2012). Essentially, in CKD, decreased phosphate excretion and decreased output of 1,25-dihydroxyvitamin D (leading to decreased intestinal Ca2+ absorption) and skeletal resistance to PTH, result in hypocalcaemia which, through activation of the CaSR, leads to increased secretion of PTH (note that a decrease in both phosphate excretion and vitamin D production may also directly lead to increased PTH secretion). Parathyroid gland hyperplasia may then develop, leading to decreased expression of CaSR and further exacerbation of the hyperparathyroidism. As for PHPT, a rise in set point for Ca2+-induced control of PTH suppression occurs making SHPT amenable to treatment with calcimimetics (Cunningham et al., 2011).
Entity Hypercalcaemia of malignancy
Note The CaSR plays a central role in hypercalcaemia of malignancy through the capacity of malignant cells expressing the CaSR to secrete PTHrP in response to agonist stimulation of the receptor (for reviews see Chattopadhyay, 2006, Ward et al., 2012). PTHrP acts like PTH to stimulate bone resorption and renal calcium reabsorption generating high Ca2+ concentrations which further stimulate the CaSR to secrete PTHrP, creating a vicious cycle. There are two types of hypercalcaemia resulting from malignancy, osteolytic hypercalcaemia and humoral hypercalcaemia (HHM), the former associated with bony metastases that act to directly resorb bone and the latter with solid tumours that secrete circulating factors that act to increase bone resorption. CaSR activation has been demonstrated to stimulate PTHrP in both breast and prostate cancer cell lines that metastasize to bone as well as in various solid tumours which are known to be associated with HHM: H-500 rat Leydig testicular cancer cells, a human lung squamous cell carcinoma cell line and a human pancreatic cell line, (FA-6) (Sanders et al., 2000; Sanders et al., 2001; Tfelt-Hansen, 2003; Morgan et al., 2006; Lorch et al., 2011). Expression of the CaSR appears to be an important predisposing factor for the generation and continued growth of bony metastases. Both breast and prostate cancer cells that express the CaSR at high levels have a greater tendency to metastasize to bone than those that express the receptor at low levels (Liao et al., 2006; Mihai et al., 2006). High Ca2+ concentrations act as a chemoattractant for breast cancer cells and this CaSR-dependent response positively correlates with the in vivo metastatic potential of several breast cancer cell lines (Saidak et al., 2009). In addition, high Ca2+ at bony metastases signalling through the CaSR may stimulate further growth of malignant cells, for example by activation of choline kinase and production of phosphocholine (Huang et al., 2009 ) or by regulating estrogen receptor-α expression and activity (Journe et al., 2004). In the prostate cancer cell line, PC-3, knockdown of the CaSR blocked Ca2+-enhanced proliferation and reduced metastatic progression in an athymic mouse model while Ca2+ stimulation enhanced PC-3 cell attachment, a critically important step in metastasis (Liao et al., 2006).
Entity Breast cancer
Note Increased dietary calcium has been shown to be protective against the development of breast cancer (Negri et al., 1996) and by contrast to the CaSR's positive role in breast cancer metastasis, the CaSR in general plays a tumour suppressor role in the development of breast cancer. This apparent paradox may best be explained by differences in the properties of primary as opposed to metastasing breast cancer cells (Ward et al., 2012). Agonist activation of the CaSR in breast cancer cells down-regulates cell proliferation, cell invasion and anchorage-independent growth as well as expression of the anti-apoptotic protein, survivin, and affords an increase in sensitivity to paclitaxel, an important drug used in the treatment of breast cancer (Liu et al., 2009a). Interestingly, the BRCA1 tumour suppressor gene which mimics these effects in breast cancer cells has been shown to do this by regulating the expression of the CaSR and therefore its effect on survivin expression and paclitaxel sensitivity (Promkan et al., 2011).
Entity Colon cancer
Note As for breast cancer, calcium has been shown to be chemopreventative for colon cancer with high levels being inhibitory and low levels favourable to human colonic cell proliferation (Lipkin, 1999, Kallay et al., 2000). Moreover, the CaSR is expressed in human colonocytes and has been shown to mediate these proliferative events (Kallay et al., 2000; Kallay et al., 2003). This becomes significant within the colonic crypts where a concentration gradient which increases from the base to the apex of the crypt allows for early proliferation of stem cells at the base of the crypt and their subsequent differentiation to functional colonic epithelial cells and finally their apoptogenesis at the apex of the crypt (reviewed by Whitfield, 2009; Ward et al., 2012). This process is regulated in part by the CaSR which is expressed in cells in response to calcium as they move up the crypt. In turn, stimulation of the CaSR signals cells to stop dividing and start differentiating. This occurs primarily by CaSR-mediated suppression of components of the wnt signalling pathway such as β-catenin/TCF-4 which control nuclear cell cycle activators such as c-myc and cyclin D1 (Chakrabarty et al., 2003; Whitfield, 2009). CaSR stimulation also produces E-cadherin which links up with β-catenin to form adherens junctions allowing cell-cell connections and at the same time sequestering β-catenin away from the nucleus (Bhagavathula et al., 2007). CaSR stimulation also leads to increased expression of the cyclin-dependent kinase inhibitors, p21 and p27, and down-regulates expression of the anti-apoptotic protein, survivin (Chakrabarty et al., 2005; Liu et al., 2009b). Taken together, it has been concluded that low levels of Ca2+ in the colon and/or a poorly expressed or functionally compromised CaSR could lead to a lack of control of cell proliferation in colonic crypt development leading to potential malignancy (Whitfield, 2009; Ward et al., 2012).
Entity Pancreatitis
Note Chronic pancreatitis develops largely as a result of a build-up of trypsin resulting in tissue injury and inflammation. Hypercalcaemia associated with inactivating mutations of the CaSR might be expected to lead to high exposure of pancreatic acinar cells to Ca2+ leading to the activation of trypsinogen to trypsin and a reduction in chymotrypsin C-mediated degradation of trypsin (Racz et al., 2002; Whitcomb, 2010). Although inactivating CaSR mutations are sometimes associated with pancreatitis, no causal link between CASR/FHH and pancreatitis could be demonstrated (Stuckey et al., 1990; Pearce et al., 1996). However, there is a stronger association between concurrent mutations in the SPINK1 and CaSR genes and pancreatitis (reviewed by Whitcomb, 2010). The SPINK1 gene encodes a protein (serine protease inhibitor Kazal 1) that blocks trypsin in response to tissue inflammation. The current belief is that neither CASR nor SPINK1 gene mutations act alone to cause pancreatitis but together and/or in association with other factors appear to contribute to the pathogenesis of this disease (Whitcomb, 2010).
Entity Cardiovascular disease/hypertension
Note There is mounting evidence that the CaSR plays an important role in the regulation of blood pressure. Stimulation of human aortic epithelial cells with spermine enhanced the production of nitrous oxide and this effect was prevented by siRNA- specific targeting of the CaSR, strongly suggesting a role for the receptor in vasodilation (Ziegelstein et al., 2006). In addition, activation of the CaSR expressed in the juxtaglomerular cells of the afferent arteriole of the kidney inhibits release of renin, thus exerting influence over the renin-angiotensin system that controls blood pressure (Atchison et al., 2010). Further to this, angiotensin II stimulates cardiac hypertrophy and this results in increased expression of the CaSR in the cardiomyocytes which, when activated, further drives angiotensin II-mediated hypertrophy (Wang et al., 2008; Magno et al., 2011b). The CaSR may also contribute to cardiac hypertrophy by IP3-mediated increases in nuclear Ca2+ and engagement of the CaN/NFAT pathway (Zhong et al., 2012). External stresses such as hypoxia-reoxygenation, ischaemia-reperfusion and the application of atherogenic agents have also been shown to increase CaSR expression in cardiac myocytes (reviewed in Magno et al., 2011b). Interestingly, the CaSR has been demonstrated to mediate the cardio-protective effects of ischaemic preconditioning (Sun and Murphy, 2010). The CaSR is also expressed in vascular smooth muscle cells of human arteries where its increased activation is associated with decreased mineralization (Alam et al., 2009). This is consistent with reduced expression of the CaSR in the atherosclerotic, highly calcified arteries found in patients with hypercalcaemia associated with secondary hyperparathyroidism and end stage CKD (Alam et al., 2009; Cunningham et al., 2011).
Entity Brain disease
Note The CaSR is implicated to play a role in Alzheimer's disease (AD), with polymorphisms in intron 4 and exon 7 of the CaSR linked to AD status (Conley et al., 2009). Both amyloid-β peptide as well as apolipoprotein E protein can activate the CaSR with the former shown to have effects on calcium permeable, non-selective cation channels in hippocampal pyramidal neurons (Ye et al., 1997; Conley et al., 2009). Nitrous oxide is responsible for the neuronal cell death characterizing late onset AD and the CaSR is necessary for the generation of a cofactor (tetrahydrobiopterin) important in the activation of nitrous oxide that is produced (in its inactive form) in response to amyloid-β peptide-mediated stimulation of the receptor (Dal Pra et al., 2005; Chiarini et al., 2009). The CaSR has also been linked to other brain diseases such as epilepsy with a mutation in the CaSR (R898Q) reported to cosegregate with idiopathic epilepsy in a family from Southern India (Kapoor et al., 2008). The CaSR appears to be critical for the expression of mRNA for myelin basic protein in preoligodendrocytes and therefore for proper myelination (Chattopadhyay et al., 2008) - in this respect it is likely that a non-functional CaSR could lead to impaired neurodevelopment.
Entity Bone disease
Note The CaSR is expressed in osteoblasts/osteocytes and osteoclasts and their precursors, bone marrow derived stromal cells, monocyte-macrophage cells, chondrocytes and haematopoietic stem cells (reviewed by Yamaguchi, 2008). Expression of a functional CaSR is critical for growth plate development/endochronal bone formation, postnatal bone development and osteoblast differentiation and the effects on these processes are independent of CaSR-mediated PTH secretion (Brown and Lian, 2008; Chang et al., 2008; Dvorak-Ewell et al., 2011). The CaSR also appears to be important postnatally for proper teeth and dental alveolar bone formation (Sun et al., 2010) and upregulation of the CaSR in chondrocytes may contribute to the progression of osteoarthritis (Burton et al., 2005). While the CaSR has not been linked to the development of osteoporosis, therapeutic agents such as strontium ranelate and calcilytic compounds which act through the CaSR have been used or proposed for its treatment (Trivedi et al., 2010; Marie et al., 2011).
Entity Other disease associations
Note Activation of the CaSR expressed in the β-cells of the islets of Langerhans of the pancreas can modulate insulin secretion and hence the receptor may play a role in diabetes mellitus (Gray et al., 2006; Squires et al., 2000). For example, L-histidine activation of the CaSR appears to negatively modulate glucose-induced insulin secretion from β-cells through changes in spatial arrangement of the CaSR and L-type voltage-dependent calcium channels that are important for Ca2+-dependent triggering of insulin release (Parkash and Asotra, 2011). Amino acid activation of the CaSR expressed in the I cells of the duodenum results in secretion of the hormone, cholecystokinin, which is important for the regulation of gall bladder contraction, pancreatic function, gastric emptying and satiety with the latter two having implications for obesity (Wang et al., 2011). In the kidney, proper regulation of AQP2 water channels and vacuolar H+-ATPase through activation of the CaSR in the collecting ducts is important for preventing kidney stones (Sands et al., 1998; Procino et al., 2004; Riccardi and Kemp, 2012) and stimulation of the CaSR expressed in podocytes of the Bowman's capsule of the kidney glomerulus, helps maintain their cytoskeletal integrity and overall survival thus preventing glomerular disease including proteinuria (Oh et al., 2011).


Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor.
Adams GB, Chabner KT, Alley IR, Olson DP, Szczepiorkowski ZM, Poznansky MC, Kos CH, Pollak MR, Brown EM, Scadden DT.
Nature. 2006 Feb 2;439(7076):599-603. Epub 2005 Dec 28.
PMID 16382241
Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells.
Alam MU, Kirton JP, Wilkinson FL, Towers E, Sinha S, Rouhi M, Vizard TN, Sage AP, Martin D, Ward DT, Alexander MY, Riccardi D, Canfield AE.
Cardiovasc Res. 2009 Feb 1;81(2):260-8. doi: 10.1093/cvr/cvn279. Epub 2008 Oct 13.
PMID 18852253
Acute activation of the calcium-sensing receptor inhibits plasma renin activity in vivo.
Atchison DK, Ortiz-Capisano MC, Beierwaltes WH.
Am J Physiol Regul Integr Comp Physiol. 2010 Oct;299(4):R1020-6. doi: 10.1152/ajpregu.00238.2010. Epub 2010 Jul 21.
PMID 20660105
Intermolecular interactions between dimeric calcium-sensing receptor monomers are important for its normal function.
Bai M, Trivedi S, Kifor O, Quinn SJ, Brown EM.
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2834-9.
PMID 10077597
Regulation of E-cadherin and beta-catenin by Ca2+ in colon carcinoma is dependent on calcium-sensing receptor expression and function.
Bhagavathula N, Hanosh AW, Nerusu KC, Appelman H, Chakrabarty S, Varani J.
Int J Cancer. 2007 Oct 1;121(7):1455-62.
PMID 17557293
Signaling of the human calcium-sensing receptor expressed in HEK293-cells is modulated by protein kinases A and C.
Bosel J, John M, Freichel M, Blind E.
Exp Clin Endocrinol Diabetes. 2003 Feb;111(1):21-6.
PMID 12605346
Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors.
Brauner-Osborne H, Wellendorph P, Jensen AA.
Curr Drug Targets. 2007 Jan;8(1):169-84. (REVIEW)
PMID 17266540
Regulation of cellular signal transduction pathways by the extracellular calcium-sensing receptor.
Brennan SC, Conigrave AD.
Curr Pharm Biotechnol. 2009 Apr;10(3):270-81. (REVIEW)
PMID 19355937
Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid.
Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC.
Nature. 1993 Dec 9;366(6455):575-80.
PMID 8255296
New insights in bone biology: unmasking skeletal effects of the extracellular calcium-sensing receptor.
Brown EM, Lian JB.
Sci Signal. 2008 Sep 2;1(35):pe40. doi: 10.1126/scisignal.135pe40.
PMID 18765829
Extracellular calcium sensing and extracellular calcium signaling.
Brown EM, MacLeod RJ.
Physiol Rev. 2001 Jan;81(1):239-297. (REVIEW)
PMID 11152759
Chondrocyte calcium-sensing receptor expression is up-regulated in early guinea pig knee osteoarthritis and modulates PTHrP, MMP-13, and TIMP-3 expression.
Burton DW, Foster M, Johnson KA, Hiramoto M, Deftos LJ, Terkeltaub R.
Osteoarthritis Cartilage. 2005 May;13(5):395-404.
PMID 15882563
Calcium-sensing receptor gene transcription is up-regulated by the proinflammatory cytokine, interleukin-1beta. Role of the NF-kappaB PATHWAY and kappaB elements.
Canaff L, Hendy GN.
J Biol Chem. 2005 Apr 8;280(14):14177-88. Epub 2005 Jan 31.
PMID 15684428
Glial cells missing-2 (GCM2) transactivates the calcium-sensing receptor gene: effect of a dominant-negative GCM2 mutant associated with autosomal dominant hypoparathyroidism.
Canaff L, Zhou X, Mosesova I, Cole DE, Hendy GN.
Hum Mutat. 2009 Jan;30(1):85-92. doi: 10.1002/humu.20827.
PMID 18712808
Parathyroid expression of calcium-sensing receptor protein and in vivo parathyroid hormone-Ca(2+) set-point in patients with primary hyperparathyroidism.
Cetani F, Picone A, Cerrai P, Vignali E, Borsari S, Pardi E, Viacava P, Naccarato AG, Miccoli P, Kifor O, Brown EM, Pinchera A, Marcocci C.
J Clin Endocrinol Metab. 2000 Dec;85(12):4789-94.
PMID 11134144
Calcium sensing receptor in human colon carcinoma: interaction with Ca(2+) and 1,25-dihydroxyvitamin D(3).
Chakrabarty S, Wang H, Canaff L, Hendy GN, Appelman H, Varani J.
Cancer Res. 2005 Jan 15;65(2):493-8.
PMID 15695391
The extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development.
Chang W, Tu C, Chen TH, Bikle D, Shoback D.
Sci Signal. 2008 Sep 2;1(35):ra1. doi: 10.1126/scisignal.1159945.
PMID 18765830
Calcium receptor expression and function in oligodendrocyte commitment and lineage progression: potential impact on reduced myelin basic protein in CaR-null mice.
Chattopadhyay N, Espinosa-Jeffrey A, Tfelt-Hansen J, Yano S, Bandyopadhyay S, Brown EM, de Vellis J.
J Neurosci Res. 2008 Aug 1;86(10):2159-67. doi: 10.1002/jnr.21662.
PMID 18438915
Type B gamma-aminobutyric acid receptors modulate the function of the extracellular Ca2+-sensing receptor and cell differentiation in murine growth plate chondrocytes.
Cheng Z, Tu C, Rodriguez L, Chen TH, Dvorak MM, Margeta M, Gassmann M, Bettler B, Shoback D, Chang W.
Endocrinology. 2007 Oct;148(10):4984-92. Epub 2007 Jul 5.
PMID 17615148
Calcium-sensing receptor (CaSR) in human brain's pathophysiology: roles in late-onset Alzheimer's disease (LOAD).
Chiarini A, Dal Pra I, Marconi M, Chakravarthy B, Whitfield JF, Armato U.
Curr Pharm Biotechnol. 2009 Apr;10(3):317-26. (REVIEW)
PMID 19355942
Cloning and characterization of two promoters for the human calcium-sensing receptor (CaSR) and changes of CaSR expression in parathyroid adenomas.
Chikatsu N, Fukumoto S, Takeuchi Y, Suzawa M, Obara T, Matsumoto T, Fujita T.
J Biol Chem. 2000 Mar 17;275(11):7553-7.
PMID 10713061
Taste receptors in the gastrointestinal tract. II. L-amino acid sensing by calcium-sensing receptors: implications for GI physiology.
Conigrave AD, Brown EM.
Am J Physiol Gastrointest Liver Physiol. 2006 Nov;291(5):G753-61. (REVIEW)
PMID 17030896
Evidence supporting a role for the calcium-sensing receptor in Alzheimer disease.
Conley YP, Mukherjee A, Kammerer C, DeKosky ST, Kamboh MI, Finegold DN, Ferrell RE.
Am J Med Genet B Neuropsychiatr Genet. 2009 Jul 5;150B(5):703-9. doi: 10.1002/ajmg.b.30896.
PMID 19035514
Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.
Cunningham J, Locatelli F, Rodriguez M.
Clin J Am Soc Nephrol. 2011 Apr;6(4):913-21. doi: 10.2215/CJN.06040710. Epub 2011 Mar 31. (REVIEW)
PMID 21454719
Roles of Ca2+ and the Ca2+-sensing receptor (CASR) in the expression of inducible NOS (nitric oxide synthase)-2 and its BH4 (tetrahydrobiopterin)-dependent activation in cytokine-stimulated adult human astrocytes.
Dal Pra I, Chiarini A, Nemeth EF, Armato U, Whitfield JF.
J Cell Biochem. 2005 Oct 1;96(2):428-38.
PMID 16052472
Osteoblast extracellular Ca2+ -sensing receptor regulates bone development, mineralization, and turnover.
Dvorak-Ewell MM, Chen TH, Liang N, Garvey C, Liu B, Tu C, Chang W, Bikle DD, Shoback DM.
J Bone Miner Res. 2011 Dec;26(12):2935-47. doi: 10.1002/jbmr.520.
PMID 21956637
The full-length calcium-sensing receptor dampens the calcemic response to 1alpha,25(OH)2 vitamin D3 in vivo independently of parathyroid hormone.
Egbuna O, Quinn S, Kantham L, Butters R, Pang J, Pollak M, Goltzman D, Brown E.
Am J Physiol Renal Physiol. 2009 Sep;297(3):F720-8. doi: 10.1152/ajprenal.00164.2009. Epub 2009 May 27.
PMID 19474191
Heterodimerization of calcium sensing receptors with metabotropic glutamate receptors in neurons.
Gama L, Wilt SG, Breitwieser GE.
J Biol Chem. 2001 Oct 19;276(42):39053-9. Epub 2001 Aug 6.
PMID 11489900
Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs.
Garrett JE, Capuano IV, Hammerland LG, Hung BC, Brown EM, Hebert SC, Nemeth EF, Fuller F.
J Biol Chem. 1995 May 26;270(21):12919-25.
PMID 7759551
Calcium-sensing receptor abrogates secretagogue- induced increases in intestinal net fluid secretion by enhancing cyclic nucleotide destruction.
Geibel J, Sritharan K, Geibel R, Geibel P, Persing JS, Seeger A, Roepke TK, Deichstetter M, Prinz C, Cheng SX, Martin D, Hebert SC.
Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9390-7. Epub 2006 Jun 7.
PMID 16760252
The functions and roles of the extracellular Ca2+-sensing receptor along the gastrointestinal tract.
Geibel JP, Hebert SC.
Annu Rev Physiol. 2009;71:205-17. doi: 10.1146/annurev.physiol.010908.163128. (REVIEW)
PMID 19575679
Agonist-driven maturation and plasma membrane insertion of calcium-sensing receptors dynamically control signal amplitude.
Grant MP, Stepanchick A, Cavanaugh A, Breitwieser GE.
Sci Signal. 2011 Nov 22;4(200):ra78. doi: 10.1126/scisignal.2002208.
PMID 22114145
Activation of the extracellular calcium-sensing receptor initiates insulin secretion from human islets of Langerhans: involvement of protein kinases.
Gray E, Muller D, Squires PE, Asare-Anane H, Huang GC, Amiel S, Persaud SJ, Jones PM.
J Endocrinol. 2006 Sep;190(3):703-10.
PMID 17003271
Calcium-sensing receptor and associated diseases.
Hendy GN, Guarnieri V, Canaff L.
Prog Mol Biol Transl Sci. 2009;89:31-95. doi: 10.1016/S1877-1173(09)89003-0. Epub 2009 Oct 7. (REVIEW)
PMID 20374733
Mutational analysis of the extracellular Ca(2+)-sensing receptor gene in human parathyroid tumors.
Hosokawa Y, Pollak MR, Brown EM, Arnold A.
J Clin Endocrinol Metab. 1995 Nov;80(11):3107-10.
PMID 7593409
Naturally occurring mutations of the extracellular Ca2+-sensing receptor: implications for its structure and function.
Hu J, Spiegel AM.
Trends Endocrinol Metab. 2003 Aug;14(6):282-8. (REVIEW)
PMID 12890593
Activation of choline kinase by extracellular Ca2+ is Ca(2+)-sensing receptor, Galpha12 and Rho-dependent in breast cancer cells.
Huang C, Hydo LM, Liu S, Miller RT.
Cell Signal. 2009 Dec;21(12):1894-900. doi: 10.1016/j.cellsig.2009.08.004. Epub 2009 Aug 27.
PMID 19716891
Mapping of the calcium-sensing receptor gene (CASR) to human chromosome 3q13.3-21 by fluorescence in situ hybridization, and localization to rat chromosome 11 and mouse chromosome 16.
Janicic N, Soliman E, Pausova Z, Seldin MF, Riviere M, Szpirer J, Szpirer C, Hendy GN.
Mamm Genome. 1995 Nov;6(11):798-801.
PMID 8597637
Extracellular calcium downregulates estrogen receptor alpha and increases its transcriptional activity through calcium-sensing receptor in breast cancer cells.
Journe F, Dumon JC, Kheddoumi N, Fox J, Laios I, Leclercq G, Body JJ.
Bone. 2004 Aug;35(2):479-88.
PMID 15268900
The extracellular calcium-sensing receptor (CaSR) on human esophagus and evidence of expression of the CaSR on the esophageal epithelial cell line (HET-1A).
Justinich CJ, Mak N, Pacheco I, Mulder D, Wells RW, Blennerhassett MG, MacLeod RJ.
Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G120-9. Epub 2007 Oct 25.
PMID 17962359
Dietary calcium and growth modulation of human colon cancer cells: role of the extracellular calcium-sensing receptor.
Kallay E, Bajna E, Wrba F, Kriwanek S, Peterlik M, Cross HS.
Cancer Detect Prev. 2000;24(2):127-36.
PMID 10917132
Molecular and functional characterization of the extracellular calcium-sensing receptor in human colon cancer cells.
Kallay E, Bonner E, Wrba F, Thakker RV, Peterlik M, Cross HS.
Oncol Res. 2003;13(12):551-9.
PMID 12899245
An idiopathic epilepsy syndrome linked to 3q13.3-q21 and missense mutations in the extracellular calcium sensing receptor gene.
Kapoor A, Satishchandra P, Ratnapriya R, Reddy R, Kadandale J, Shankar SK, Anand A.
Ann Neurol. 2008 Aug;64(2):158-67. doi: 10.1002/ana.21428.
PMID 18756473
The calcium-sensing receptor is localized in caveolin-rich plasma membrane domains of bovine parathyroid cells.
Kifor O, Diaz R, Butters R, Kifor I, Brown EM.
J Biol Chem. 1998 Aug 21;273(34):21708-13.
PMID 9705306
Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism.
Kifor O, Moore FD Jr, Wang P, Goldstein M, Vassilev P, Kifor I, Hebert SC, Brown EM.
J Clin Endocrinol Metab. 1996 Apr;81(4):1598-606.
PMID 8636374
Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis.
Liao J, Schneider A, Datta NS, McCauley LK.
Cancer Res. 2006 Sep 15;66(18):9065-73.
PMID 16982748
Preclinical and early human studies of calcium and colon cancer prevention.
Lipkin M.
Ann N Y Acad Sci. 1999;889:120-7. (REVIEW)
PMID 10668488
Calcium and calcium sensing receptor modulates the expression of thymidylate synthase, NAD(P)H:quinone oxidoreductase 1 and survivin in human colon carcinoma cells: promotion of cytotoxic response to mitomycin C and fluorouracil.
Liu G, Hu X, Varani J, Chakrabarty S.
Mol Carcinog. 2009b Mar;48(3):202-11. doi: 10.1002/mc.20470.
PMID 18618519
The calcium-sensing receptor is necessary for the rapid development of hypercalcemia in human lung squamous cell carcinoma.
Lorch G, Viatchenko-Karpinski S, Ho HT, Dirksen WP, Toribio RE, Foley J, Gyorke S, Rosol TJ.
Neoplasia. 2011 May;13(5):428-38.
PMID 21532883
Extracellular calcium controls background current and neuronal excitability via an UNC79-UNC80-NALCN cation channel complex.
Lu B, Zhang Q, Wang H, Wang Y, Nakayama M, Ren D.
Neuron. 2010 Nov 4;68(3):488-99. doi: 10.1016/j.neuron.2010.09.014.
PMID 21040849
Testin, a novel binding partner of the calcium-sensing receptor, enhances receptor-mediated Rho-kinase signalling.
Magno AL, Ingley E, Brown SJ, Conigrave AD, Ratajczak T, Ward BK.
Biochem Biophys Res Commun. 2011a Sep 9;412(4):584-9. doi: 10.1016/j.bbrc.2011.07.132. Epub 2011 Aug 6.
PMID 21843504
The calcium-sensing receptor: a molecular perspective.
Magno AL, Ward BK, Ratajczak T.
Endocr Rev. 2011b Feb;32(1):3-30. doi: 10.1210/er.2009-0043. Epub 2010 Aug 20. (REVIEW)
PMID 20729338
The calcium-sensing receptor couples to Galpha(s) and regulates PTHrP and ACTH secretion in pituitary cells.
Mamillapalli R, Wysolmerski J.
J Endocrinol. 2010 Mar;204(3):287-97. doi: 10.1677/JOE-09-0183. Epub 2009 Dec 23.
PMID 20032198
How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis.
Marie PJ, Felsenberg D, Brandi ML.
Osteoporos Int. 2011 Jun;22(6):1659-67. doi: 10.1007/s00198-010-1369-0. Epub 2010 Sep 2. (REVIEW)
PMID 20812008
The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis.
Mentaverri R, Yano S, Chattopadhyay N, Petit L, Kifor O, Kamel S, Terwilliger EF, Brazier M, Brown EM.
FASEB J. 2006 Dec;20(14):2562-4. Epub 2006 Oct 31.
PMID 17077282
Expression of the calcium receptor in human breast cancer--a potential new marker predicting the risk of bone metastases.
Mihai R, Stevens J, McKinney C, Ibrahim NB.
Eur J Surg Oncol. 2006 Jun;32(5):511-5. Epub 2006 Mar 24.
PMID 16564154
Calcium insensitivity of FA-6, a cell line derived from a pancreatic cancer associated with humoral hypercalcemia, is mediated by the significantly reduced expression of the Calcium Sensitive Receptor transduction component p38 MAPK.
Morgan R, Fairfax B, Pandha HS.
Mol Cancer. 2006 Nov 1;5:51.
PMID 17078869
Adenomatous human parathyroid cells exhibit impaired sensitivity to L-amino acids.
Mun HC, Brennan SC, Delbridge L, Wilkinson M, Brown EM, Conigrave AD.
J Clin Endocrinol Metab. 2009 Sep;94(9):3567-74. doi: 10.1210/jc.2008-2714. Epub 2009 Jun 30.
PMID 19567535
Intake of selected micronutrients and the risk of breast cancer.
Negri E, La Vecchia C, Franceschi S, D'Avanzo B, Talamini R, Parpinel M, Ferraroni M, Filiberti R, Montella M, Falcini F, Conti E, Decarli A.
Int J Cancer. 1996 Jan 17;65(2):140-4.
PMID 8567108
Calcimimetics with potent and selective activity on the parathyroid calcium receptor.
Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF.
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):4040-5.
PMID 9520489
Stimulation of the calcium-sensing receptor stabilizes the podocyte cytoskeleton, improves cell survival, and reduces toxin-induced glomerulosclerosis.
Oh J, Beckmann J, Bloch J, Hettgen V, Mueller J, Li L, Hoemme M, Gross ML, Penzel R, Mundel P, Schaefer F, Schmitt CP.
Kidney Int. 2011 Sep;80(5):483-92. doi: 10.1038/ki.2011.105. Epub 2011 Apr 20.
PMID 21508926
Involvement of the calcium-sensing receptor in human taste perception.
Ohsu T, Amino Y, Nagasaki H, Yamanaka T, Takeshita S, Hatanaka T, Maruyama Y, Miyamura N, Eto Y.
J Biol Chem. 2010 Jan 8;285(2):1016-22. doi: 10.1074/jbc.M109.029165. Epub 2009 Nov 5.
PMID 19892707
L-histidine sensing by calcium sensing receptor inhibits voltage-dependent calcium channel activity and insulin secretion in β-cells.
Parkash J, Asotra K.
Life Sci. 2011 Feb 28;88(9-10):440-6. doi: 10.1016/j.lfs.2010.12.022. Epub 2011 Jan 8.
PMID 21219913
Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study.
Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D.
J Clin Endocrinol Metab. 2009 Dec;94(12):4860-7. doi: 10.1210/jc.2009-1472. Epub 2009 Oct 16.
PMID 19837909
Calcium-sensing receptor mutations in familial hypocalciuric hypercalcaemia with recurrent pancreatitis.
Pearce SH, Wooding C, Davies M, Tollefsen SE, Whyte MP, Thakker RV.
Clin Endocrinol (Oxf). 1996 Dec;45(6):675-80.
PMID 9039332
Calcium-sensing receptor dimerizes in the endoplasmic reticulum: biochemical and biophysical characterization of CASR mutants retained intracellularly.
Pidasheva S, Grant M, Canaff L, Ercan O, Kumar U, Hendy GN.
Hum Mol Genet. 2006 Jul 15;15(14):2200-9. Epub 2006 Jun 1.
PMID 16740594
Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation.
Pollak MR, Brown EM, Estep HL, McLaine PN, Kifor O, Park J, Hebert SC, Seidman CE, Seidman JG.
Nat Genet. 1994 Nov;8(3):303-7.
PMID 7874174
Extracellular calcium antagonizes forskolin-induced aquaporin 2 trafficking in collecting duct cells.
Procino G, Carmosino M, Tamma G, Gouraud S, Laera A, Riccardi D, Svelto M, Valenti G.
Kidney Int. 2004 Dec;66(6):2245-55.
PMID 15569313
BRCA1 suppresses the expression of survivin and promotes sensitivity to paclitaxel through the calcium sensing receptor (CaSR) in human breast cancer cells.
Promkan M, Liu G, Patmasiriwat P, Chakrabarty S.
Cell Calcium. 2011 Feb;49(2):79-88. doi: 10.1016/j.ceca.2011.01.003. Epub 2011 Feb 5.
PMID 21296416
Extracellular calcium sensing receptor in human pancreatic cells.
Racz GZ, Kittel A, Riccardi D, Case RM, Elliott AC, Varga G.
Gut. 2002 Nov;51(5):705-11.
PMID 12377811
Identification of the sites of N-linked glycosylation on the human calcium receptor and assessment of their role in cell surface expression and signal transduction.
Ray K, Clapp P, Goldsmith PK, Spiegel AM.
J Biol Chem. 1998 Dec 18;273(51):34558-67.
PMID 9852126
The carboxyl terminus of the human calcium receptor. Requirements for cell-surface expression and signal transduction.
Ray K, Fan GF, Goldsmith PK, Spiegel AM.
J Biol Chem. 1997 Dec 12;272(50):31355-61.
PMID 9395465
The calcium-sensing receptor beyond extracellular calcium homeostasis: conception, development, adult physiology, and disease.
Riccardi D, Kemp PJ.
Annu Rev Physiol. 2012;74:271-97. doi: 10.1146/annurev-physiol-020911-153318. Epub 2011 Oct 17. (REVIEW)
PMID 22017175
Destabilization of parathyroid hormone mRNA by extracellular Ca2+ and the calcimimetic R-568 in parathyroid cells: role of cytosolic Ca and requirement for gene transcription.
Ritter CS, Pande S, Krits I, Slatopolsky E, Brown AJ.
J Mol Endocrinol. 2008 Jan;40(1):13-21.
PMID 18096993
Expression and functional assessment of an alternatively spliced extracellular Ca2+-sensing receptor in growth plate chondrocytes.
Rodriguez L, Tu C, Cheng Z, Chen TH, Bikle D, Shoback D, Chang W.
Endocrinology. 2005a Dec;146(12):5294-303. Epub 2005 Sep 15.
PMID 16166224
The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism.
Rodriguez M, Nemeth E, Martin D.
Am J Physiol Renal Physiol. 2005b Feb;288(2):F253-64. Epub 2004 Oct 26. (REVIEW)
PMID 15507543
Extracellular calcium promotes the migration of breast cancer cells through the activation of the calcium sensing receptor.
Saidak Z, Boudot C, Abdoune R, Petit L, Brazier M, Mentaverri R, Kamel S.
Exp Cell Res. 2009 Jul 15;315(12):2072-80. doi: 10.1016/j.yexcr.2009.03.003. Epub 2009 Mar 13.
PMID 19285978
Ca(2+)-sensing receptor expression and PTHrP secretion in PC-3 human prostate cancer cells.
Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Brown EM.
Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1267-74.
PMID 11701443
Vasopressin-elicited water and urea permeabilities are altered in IMCD in hypercalcemic rats.
Sands JM, Flores FX, Kato A, Baum MA, Brown EM, Ward DT, Hebert SC, Harris HW.
Am J Physiol. 1998 May;274(5 Pt 2):F978-85.
PMID 9612337
Clinical and molecular genetics of parathyroid neoplasms.
Sharretts JM, Simonds WF.
Best Pract Res Clin Endocrinol Metab. 2010 Jun;24(3):491-502. doi: 10.1016/j.beem.2010.01.003. (REVIEW)
PMID 20833339
The extracellular calcium-sensing receptor on human beta-cells negatively modulates insulin secretion.
Squires PE, Harris TE, Persaud SJ, Curtis SB, Buchan AM, Jones PM.
Diabetes. 2000 Mar;49(3):409-17.
PMID 10868962
Familial hypocalciuric hypercalcaemia and pancreatitis: no causal link proven.
Stuckey BG, Gutteridge DH, Kent GN, Reed WD.
Aust N Z J Med. 1990 Oct;20(5):718-9, 725.
PMID 2285390
Calcium-sensing receptor: a sensor and mediator of ischemic preconditioning in the heart.
Sun J, Murphy E.
Am J Physiol Heart Circ Physiol. 2010 Nov;299(5):H1309-17. doi: 10.1152/ajpheart.00373.2010. Epub 2010 Sep 10.
PMID 20833954
Alterations in phosphorus, calcium and PTHrP contribute to defects in dental and dental alveolar bone formation in calcium-sensing receptor-deficient mice.
Sun W, Sun W, Liu J, Zhou X, Xiao Y, Karaplis A, Pollak MR, Brown E, Goltzman D, Miao D.
Development. 2010 Mar;137(6):985-92. doi: 10.1242/dev.045898. Epub 2010 Feb 11.
PMID 20150282
The calcium-sensing receptor in normal physiology and pathophysiology: a review.
Tfelt-Hansen J, Brown EM.
Crit Rev Clin Lab Sci. 2005;42(1):35-70. (REVIEW)
PMID 15697170
Calcium-sensing receptor modulates cell adhesion and migration via integrins.
Tharmalingam S, Daulat AM, Antflick JE, Ahmed SM, Nemeth EF, Angers S, Conigrave AD, Hampson DR.
J Biol Chem. 2011 Nov 25;286(47):40922-33. doi: 10.1074/jbc.M111.265454. Epub 2011 Oct 3.
PMID 21969374
Investigational anabolic therapies for osteoporosis.
Trivedi R, Goswami R, Chattopadhyay N.
Expert Opin Investig Drugs. 2010 Aug;19(8):995-1005. doi: 10.1517/13543784.2010.501077. (REVIEW)
PMID 20629616
Inactivation of the calcium sensing receptor inhibits E-cadherin-mediated cell-cell adhesion and calcium-induced differentiation in human epidermal keratinocytes.
Tu CL, Chang W, Xie Z, Bikle DD.
J Biol Chem. 2008 Feb 8;283(6):3519-28. Epub 2007 Dec 7.
PMID 18065418
The calcium-sensing receptor regulates mammary gland parathyroid hormone-related protein production and calcium transport.
VanHouten J, Dann P, McGeoch G, Brown EM, Krapcho K, Neville M, Wysolmerski JJ.
J Clin Invest. 2004 Feb;113(4):598-608.
PMID 14966569
Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome.
Vargas-Poussou R, Huang C, Hulin P, Houillier P, Jeunemaitre X, Paillard M, Planelles G, Dechaux M, Miller RT, Antignac C.
J Am Soc Nephrol. 2002 Sep;13(9):2259-66.
PMID 12191970
Involvement of calcium-sensing receptor in cardiac hypertrophy-induced by angiotensinII through calcineurin pathway in cultured neonatal rat cardiomyocytes.
Wang LN, Wang C, Lin Y, Xi YH, Zhang WH, Zhao YJ, Li HZ, Tian Y, Lv YJ, Yang BF, Xu CQ.
Biochem Biophys Res Commun. 2008 May 2;369(2):584-9. doi: 10.1016/j.bbrc.2008.02.053. Epub 2008 Feb 22.
PMID 18295598
Amino acids stimulate cholecystokinin release through the Ca2+-sensing receptor.
Wang Y, Chandra R, Samsa LA, Gooch B, Fee BE, Cook JM, Vigna SR, Grant AO, Liddle RA.
Am J Physiol Gastrointest Liver Physiol. 2011 Apr;300(4):G528-37. doi: 10.1152/ajpgi.00387.2010. Epub 2010 Dec 23.
PMID 21183662
The role of the calcium-sensing receptor in human disease.
Ward BK, Magno AL, Walsh JP, Ratajczak T.
Clin Biochem. 2012 Aug;45(12):943-53. doi: 10.1016/j.clinbiochem.2012.03.034. Epub 2012 Apr 5. (REVIEW)
PMID 22503956
The calcium receptor modulates the hyperpolarization-activated current in subfornical organ neurons.
Washburn DL, Anderson JW, Ferguson AV.
Neuroreport. 2000 Sep 28;11(14):3231-5.
PMID 11043554
Genetic aspects of pancreatitis.
Whitcomb DC.
Annu Rev Med. 2010;61:413-24. doi: 10.1146/ (REVIEW)
PMID 20059346
Calcium, calcium-sensing receptor and colon cancer.
Whitfield JF.
Cancer Lett. 2009 Mar 8;275(1):9-16. doi: 10.1016/j.canlet.2008.07.001. Epub 2008 Aug 23. (REVIEW)
PMID 18725175
The calcium-sensing receptor in bone.
Yamaguchi T.
J Bone Miner Metab. 2008;26(4):301-11. doi: 10.1007/s00774-008-0843-7. Epub 2008 Jul 4. (REVIEW)
PMID 18600395
Calcium-sensing receptor in the brain.
Yano S, Brown EM, Chattopadhyay N.
Cell Calcium. 2004 Mar;35(3):257-64. (REVIEW)
PMID 15200149
Amyloid-beta proteins activate Ca(2+)-permeable channels through calcium-sensing receptors.
Ye C, Ho-Pao CL, Kanazirska M, Quinn S, Rogers K, Seidman CE, Seidman JG, Brown EM, Vassilev PM.
J Neurosci Res. 1997 Mar 1;47(5):547-54.
PMID 9067864
The extracellular calcium-sensing receptor dimerizes through multiple types of intermolecular interactions.
Zhang Z, Sun S, Quinn SJ, Brown EM, Bai M.
J Biol Chem. 2001 Feb 16;276(7):5316-22. Epub 2000 Nov 7.
PMID 11069904
Calcium sensing receptor regulates cardiomyocyte function through nuclear calcium.
Zhong X, Liu J, Lu F, Wang Y, Zhao Y, Dong S, Leng X, Jia J, Ren H, Xu C, Zhang W.
Cell Biol Int. 2012 Oct 1;36(10):937-43. doi: 10.1042/CBI20110594.
PMID 22708524
Expression of a functional extracellular calcium-sensing receptor in human aortic endothelial cells.
Ziegelstein RC, Xiong Y, He C, Hu Q.
Biochem Biophys Res Commun. 2006 Mar 31;342(1):153-63. Epub 2006 Feb 3.
PMID 16472767


This paper should be referenced as such :
Ward, B ; Magno, A ; Ratajczak, T
CASR (Calcium-Sensing Receptor)
Atlas Genet Cytogenet Oncol Haematol. 2014;18(4):247-259.
Free journal version : [ pdf ]   [ DOI ]

External links


HGNC (Hugo)CASR   1514
Entrez_Gene (NCBI)CASR    calcium sensing receptor
AliasesCAR; EIG8; FHH; FIH; 
GeneCards (Weizmann)CASR
Ensembl hg19 (Hinxton)ENSG00000036828 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000036828 [Gene_View]  ENSG00000036828 [Sequence]  chr3:122184327-122291628 [Contig_View]  CASR [Vega]
ICGC DataPortalENSG00000036828
Genatlas (Paris)CASR
SOURCE (Princeton)CASR
Genetics Home Reference (NIH)CASR
Genomic and cartography
GoldenPath hg38 (UCSC)CASR  -     chr3:122184327-122291628 +  3q13.33-q21.1   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)CASR  -     3q13.33-q21.1   [Description]    (hg19-Feb_2009)
GoldenPathCASR - 3q13.33-q21.1 [CytoView hg19]  CASR - 3q13.33-q21.1 [CytoView hg38]
Genome Data Viewer NCBICASR [Mapview hg19]  
OMIM145980   239200   601198   601199   612899   
Gene and transcription
Genbank (Entrez)BC104999 BC112236 BP388878 D50855 FJ360896
RefSeq transcript (Entrez)NM_000388 NM_001178065
Consensus coding sequences : CCDS (NCBI)CASR
Gene ExpressionCASR [ NCBI-GEO ]   CASR [ EBI - ARRAY_EXPRESS ]   CASR [ SEEK ]   CASR [ MEM ]
Gene Expression Viewer (FireBrowse)CASR [ Firebrowse - Broad ]
GenevisibleExpression of CASR in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)846
GTEX Portal (Tissue expression)CASR
Human Protein AtlasENSG00000036828-CASR [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtP41180   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP41180  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP41180
Domaine pattern : Prosite (Expaxy)G_PROTEIN_RECEP_F3_1 (PS00979)    G_PROTEIN_RECEP_F3_2 (PS00980)    G_PROTEIN_RECEP_F3_3 (PS00981)    G_PROTEIN_RECEP_F3_4 (PS50259)   
Domains : Interpro (EBI)ANF_lig-bd_rcpt    GPCR_3    GPCR_3_9-Cys_dom    GPCR_3_9-Cys_sf    GPCR_3_C    GPCR_3_Ca_sens_rcpt-rel    GPCR_3_CS    Peripla_BP_I   
Domain families : Pfam (Sanger)7tm_3 (PF00003)    ANF_receptor (PF01094)    NCD3G (PF07562)   
Domain families : Pfam (NCBI)pfam00003    pfam01094    pfam07562   
Conserved Domain (NCBI)CASR
PDB (RSDB)5FBH    5FBK    5K5S    5K5T   
PDB Europe5FBH    5FBK    5K5S    5K5T   
PDB (PDBSum)5FBH    5FBK    5K5S    5K5T   
PDB (IMB)5FBH    5FBK    5K5S    5K5T   
Structural Biology KnowledgeBase5FBH    5FBK    5K5S    5K5T   
SCOP (Structural Classification of Proteins)5FBH    5FBK    5K5S    5K5T   
CATH (Classification of proteins structures)5FBH    5FBK    5K5S    5K5T   
AlphaFold pdb e-kbP41180   
Human Protein Atlas [tissue]ENSG00000036828-CASR [tissue]
Protein Interaction databases
IntAct (EBI)P41180
Ontologies - Pathways
Ontology : AmiGOossification  response to ischemia  phosphatidylinositol phospholipase C activity  G protein-coupled receptor activity  G protein-coupled receptor activity  integrin binding  calcium ion binding  calcium ion binding  detection of calcium ion  detection of calcium ion  protein binding  nucleus  cytoplasm  plasma membrane  integral component of plasma membrane  integral component of plasma membrane  cellular calcium ion homeostasis  cellular calcium ion homeostasis  apoptotic process  G protein-coupled receptor signaling pathway  G protein-coupled receptor signaling pathway  G protein-coupled receptor signaling pathway  adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway  phospholipase C-activating G protein-coupled receptor signaling pathway  JNK cascade  chemosensory behavior  positive regulation of cell population proliferation  anatomical structure morphogenesis  cell surface  positive regulation of gene expression  basolateral plasma membrane  apical plasma membrane  amino acid binding  protein kinase binding  positive regulation of insulin secretion  positive regulation of ATPase activity  bile acid secretion  cellular response to hepatocyte growth factor stimulus  vasodilation  protein homodimerization activity  neuronal cell body  axon terminus  ion channel binding  positive regulation of vasoconstriction  branching morphogenesis of an epithelial tube  positive regulation of positive chemotaxis  regulation of calcium ion transport  fat pad development  positive regulation of ERK1 and ERK2 cascade  calcium ion import  cellular response to vitamin D  cellular response to glucose stimulus  cellular response to low-density lipoprotein particle stimulus  cellular response to hypoxia  response to fibroblast growth factor  positive regulation of calcium ion import  cellular response to peptide  chloride transmembrane transport  
Ontology : EGO-EBIossification  response to ischemia  phosphatidylinositol phospholipase C activity  G protein-coupled receptor activity  G protein-coupled receptor activity  integrin binding  calcium ion binding  calcium ion binding  detection of calcium ion  detection of calcium ion  protein binding  nucleus  cytoplasm  plasma membrane  integral component of plasma membrane  integral component of plasma membrane  cellular calcium ion homeostasis  cellular calcium ion homeostasis  apoptotic process  G protein-coupled receptor signaling pathway  G protein-coupled receptor signaling pathway  G protein-coupled receptor signaling pathway  adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway  phospholipase C-activating G protein-coupled receptor signaling pathway  JNK cascade  chemosensory behavior  positive regulation of cell population proliferation  anatomical structure morphogenesis  cell surface  positive regulation of gene expression  basolateral plasma membrane  apical plasma membrane  amino acid binding  protein kinase binding  positive regulation of insulin secretion  positive regulation of ATPase activity  bile acid secretion  cellular response to hepatocyte growth factor stimulus  vasodilation  protein homodimerization activity  neuronal cell body  axon terminus  ion channel binding  positive regulation of vasoconstriction  branching morphogenesis of an epithelial tube  positive regulation of positive chemotaxis  regulation of calcium ion transport  fat pad development  positive regulation of ERK1 and ERK2 cascade  calcium ion import  cellular response to vitamin D  cellular response to glucose stimulus  cellular response to low-density lipoprotein particle stimulus  cellular response to hypoxia  response to fibroblast growth factor  positive regulation of calcium ion import  cellular response to peptide  chloride transmembrane transport  
NDEx NetworkCASR
Atlas of Cancer Signalling NetworkCASR
Wikipedia pathwaysCASR
Orthology - Evolution
GeneTree (enSembl)ENSG00000036828
Phylogenetic Trees/Animal Genes : TreeFamCASR
Homologs : HomoloGeneCASR
Homology/Alignments : Family Browser (UCSC)CASR
Gene fusions - Rearrangements
Fusion : MitelmanFAM162A::CASR [3q21.1/3q21.1]  
Fusion : MitelmanLPP::CASR [3q28/3q21.1]  
Fusion : MitelmanSUCLA2::CASR [13q14.2/3q21.1]  
Fusion : QuiverCASR
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerCASR [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)CASR
Exome Variant ServerCASR
GNOMAD BrowserENSG00000036828
Varsome BrowserCASR
ACMGCASR variants
Genomic Variants (DGV)CASR [DGVbeta]
DECIPHERCASR [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisCASR 
ICGC Data PortalCASR 
TCGA Data PortalCASR 
Broad Tumor PortalCASR
OASIS PortalCASR [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICCASR  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DCASR
Mutations and Diseases : HGMDCASR
LOVD (Leiden Open Variation Database)[gene] [transcripts] [variants]
DgiDB (Drug Gene Interaction Database)CASR
DoCM (Curated mutations)CASR
CIViC (Clinical Interpretations of Variants in Cancer)CASR
NCG (London)CASR
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
OMIM145980    239200    601198    601199    612899   
Orphanet508    20051    5543    12300   
Genetic Testing Registry CASR
NextProtP41180 [Medical]
Target ValidationCASR
Huge Navigator CASR [HugePedia]
ClinGenCASR (curated)
Clinical trials, drugs, therapy
Protein Interactions : CTDCASR
Pharm GKB GenePA26097
Pharm GKB PathwaysPA152530845   
Clinical trialCASR
DataMed IndexCASR
PubMed479 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Oct 8 21:14:10 CEST 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us